Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer (Q34062336)

30 July 2017

1 reference

title

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer (English)

1 reference

30 July 2017

M D Shelley

1

1 reference

30 July 2017

J B Court

2

1 reference

30 July 2017

H Kynaston

3

1 reference

30 July 2017

T J Wilt

4

1 reference

30 July 2017

R G Fish

5

1 reference

30 July 2017

M Mason

6

1 reference

30 July 2017

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

30 July 2017

published in

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

CD001986

1 reference

Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Prospective randomized study for prophylactic effect

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001986

The treated natural history of high risk superficial bladder cancer: 15-year outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001986

Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001986

Factors affecting recurrence and progression in superficial bladder tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001986

Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001986

Biology and management of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001986

Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial

21 January 2018

1 reference

12 December 2020

Intravesical Bacillus Calmette-Guérin prophylactic treatment for superficial bladder tumors: results of a controlled prospective study

1 reference

12 December 2020

Bladder cancer immunotherapy

1 reference

12 December 2020

Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

1 reference

12 December 2020

BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses

1 reference

12 December 2020

Marker tumour response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)

1 reference

12 December 2020

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

1 reference

12 December 2020

Bacillus Calmette-Guerin immunotherapy for bladder cancer

1 reference

12 December 2020

Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma

1 reference

12 December 2020

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer

1 reference

12 December 2020

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

12 December 2020

[Results of treatment of superficial vesical tumors by transurethral resection alone and transurethral resection followed by an intravesical instillation of Calmette-Guerin bacillus]

1 reference

12 December 2020

Effect of intravesical bacillus calmette-guerin (BCG) on carcinomain situ of the bladder

1 reference

12 December 2020

BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group

1 reference

12 December 2020

[Adjuvant BCG immunotherapy in the management of superficial bladder tumors]

1 reference

12 December 2020

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer

1 reference

12 December 2020

Cancer statistics, 1995.

1 reference

12 December 2020

Prophylactic maltose tetrapalmitate and bacillus Calmette-Guerin immunotherapy of recurrent superficial bladder tumors: preliminary report

1 reference

12 December 2020

BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.

1 reference

12 December 2020

A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?

1 reference

12 December 2020

Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.

1 reference

12 December 2020

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

12 December 2020

Low-dose BCG in the therapy of superficial neoplasms of the bladder

1 reference

12 December 2020

Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors

1 reference

12 December 2020

Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder

1 reference

12 December 2020

The role of surgery in the multimodality treatment of bladder cancer

1 reference

12 December 2020

10.1002/14651858.CD001986

Identifiers

DOI

1 reference

30 July 2017

0 references

1 reference